SkinBioTherapeutics PLC (LON:SBTX)

SkinBioTherapeutics PLC (LON:SBTX)


Share Price
20.75 p
Change
-0.5 (-2.35 %)
Market Cap
£26.58 m
Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics PLC

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain at The University of Manchester.

The SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when...

EPIC: SBTX
Market: AIM:SBTX
52-week High/Low: 29.93p / 12.34p
Sector: Pharma & Biotech
Market Cap: £26.58 m
Website: www.skinbiotherapeutics.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of SkinBioTherapeutics PLC


Woman touching face
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance

SkinBioTherapeutics PLC Snapshot

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain at The University of Manchester.

The SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.

SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.

 

SkinBioTherapeutics

 

The Microbiome

The microbiome is the genetic material of all the microbes - bacteria, fungi, protozoa and viruses - that live on and inside the human body. The microbiome has essential beneficial functions relevant to supporting life and it is a fundamental component of human physiology. Changes in the microbiome can trigger changes in human cellular activities, resulting in disease or contribute to its progression.


The Human Microbiome

  • The human body has around 10X more bacteria within it, and on it than human cells
  • The collective name for all the genes in all the bacteria is 'the microbiome'
  • The microbiome consists of around 1000,000 genes - humans have around 23,000
  • The microbiome has huge potential to change how the body functions

Skinbiotix

SkinBioTherapeutics uses lysates (extracts) of probiotic bacteria that have been shown to:

  • Increase the skins barrier integrity by enhancing the formation of multi-protein complexes called 'tight junctions'. Tight junctions seal the space between adjacent gut cells to prevent the passage of toxins, molecules and ions through these spaces
  • Protect the Skin from infection by outcompeting harmful pathogens
  • Increase the rate of Skin healing in response to injury
SkinBioTherapeutics

 

United Kingdom.

Martin Hunt, Non-Executive Chairman(aged 60)
Martin Hunt has over 30 years' experience in large multi-nationals, start-ups and public companies with a strong track record of management success and fund raising in the life science sector. His previous roles include CEO of biomaterials company Tissue Science Laboratories plc. Mr Hunt is Programme Director of the NIHR translational funding programme Invention for Innovation (i4i) and a member of the NIHR Strategy Board.

Dr Catherine O'Neill, Chief Executive Officer(aged 53)
Dr O'Neill is an accomplished biologist and a leader in human-bacterial interactions. Dr O'Neill previously founded a specialist dermatology business, Curapel Limited, leading the company through its formation and development stage. As an innovator and expert Dr O'Neill has worked as an adviser for a number of skincare businesses and brand owners. This includes delivering technology from the lab, through development and onto new product concepts in partnership with global corporations. Dr O'Neill is a biochemist by training and has previously led multidisciplinary research teams as a senior lecturer at the University of Manchester.

Stuart Ashman, CEO designate(aged 52)
Stuart has over 20 years' experience in the medical device and life science sectors and most recently was CEO of Onbone Oy ("Onbone"), a Finnish private equity-backed medical device company. In this role, he successfully established a global sales force and distribution network and led the growth of a multi-million pound business.

Prior to Onbone, Mr Ashman was President/CEO of Andover Healthcare Inc., a US-based wound management manufacturer, and before then, was President/CEO of TI Group, a UK-based medical/engineering company. Stuart also served as Senior VP, Global Sales & Strategic Marketing, BSN Medical (Biersdorf, Smith and Nephew) and was Director of Sales & Marketing at Smith & Nephew Plc, in its Woundcare, Casting & Bandaging division.

Doug Quinn, Chief Financial Officer(aged 51)
Doug Quinn has spent the last 15 years involved in start-up and early stage businesses helping to manage them through subsequent levels of growth and secure the requisite funding. Mr Quinn has operational experience both within finance and across other business functions as well as considerable corporate finance experience, including in public markets. He was previously CFO at AIM listed Arthro Kinetics Plc and is currently CFO with regenerative medicine company Videregen and prior to joining SkinBioTherapeutics was CFO with University of Manchester spinout Gelexir Healthcare.

Stephen O'Hara, Non-Executive Director(aged 59)
Stephen O'Hara spent 20 years working for the National Health Service (NHS) where he was responsible for delivering microbiology services to a large university teaching hospital. Mr O'Hara left the NHS in 2000 to set up Acolyte Biomedica Limited (Acolyte), which developed rapid diagnostics for healthcare acquired infections such as MRSA. Acolyte was sold to 3M in 2007 where he became Director of Microbiology. Mr O'Hara left 3M in 2009 to become a Director at Taunton and Somerset Foundation Trust. In 2011 he founded Intelligent Biotech Limited as a vehicle to identify technologies and market opportunities in healthcare, which has enabled him to identify the emerging potential of the human microbiome and set up OptiBiotix.

Dr Catherine Prescott, Non-Executive Director(aged 58)
Catherine has over two decades of experience in research, management and business in the biotechnology, pharmaceutical and venture capital sectors. Founder/Director of the consultancy Biolatris Ltd., Non-Executive Director of Videregen Ltd., Chair of the Trakcel Ltd Advisory Board, Translation Advisory Group member of the Babraham Institute, and Member of the Board of Trustees IMET2000. She is also a visiting professor at Kings College (London) teaching on the MSc programme 'Cellular Therapies from bench to market' and Senior Associate for the Masters in Bioscience Enterprise (Cambridge University).

Please click here for major shareholders 

Contact SkinBioTherapeutics
If you would like to discuss any aspect of our company with one of our team please do not hesitate to contact us.

Address
SkinBioTherapeutics PLC
15 Silk House
Park Green
Macclesfield
SK11 7QJ

Phone
+44 161 468 2760

Email
Please complete the contact form or email to one of the addresses below;

[email protected]
[email protected]
[email protected]
[email protected]
[email protected]

Nominated Adviser

Cairn Financial Advisers LLP
Cheyne House, Crown Court
62-63 Cheapside
London
EC2V 6AX
United Kingdom
+44 (0)20 7213 0880

Brokers

SP Angel Corporate Finance LLP
Prince Frederick House
35-39 Maddox Street
London
W15 2PP
+44 20 3470 0470

Turner Pope Investments (TPI) Ltd
Becket House
36 Old Jewry
London
EC2R 8DD
020 3621 4140
Financial PR
Instinctif Partners
65 Gresham Street
London
EC2V 7NQ
United Kingdom
+44 (0)20 7457 2020

Registrar

Share Registrars Limited
The Courtyard
17 West Street
Farnham
GU9 7DR
United Kingdom
+44 (0)1252 821 390

Auditors and Reporting Accountants

Jeffreys Henry LLP
Finsgate
5-7 Cranwood Street
London
EC1V 9EE
United Kingdom
+44 (0)20 7309 2222

Legal Adviser to the Company

Keystone Law Limited
48 Chancery Lane
London
WC2A 1JFM
020 3319 3700

Columns Including SBTX

VIEW ALL

Market Reports Including SBTX

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use